When an Am Law 100 Firm Creates a 'Longevity & Healthspan' Group, It's No Longer Niche
An Am Law 100 firm launches a group dedicated to longevity/healthspan: a signal that regulation, privacy, and IP are becoming the real battleground.
Some news looks “corporate” on the surface, but it’s exactly the kind that determines who wins in clinical longevity.
Source: ArentFox Schiff (press release)
On January 28, 2026, ArentFox Schiff (Am Law 100) announced the launch of a dedicated Longevity & Healthspan group. Translation: the ecosystem is now big enough — and complex enough — for regulation, data privacy, and IP to become recurring work, not rare cases.
What the Announcement Says (The Essentials)
The press release frames it as a cross-practice “desk” spanning: health care, regulatory (FDA/medical devices), privacy and data governance, patents, corporate, and government relations.
It explicitly cites the market perimeter: biotech, diagnostics and DTC testing, imaging, wearables, AI platforms… and also longevity clinics.
The Concrete Legal Challenges Facing Clinics
The ArentFox Schiff announcement is generic by design — it’s a press release, not a legal brief. But the fronts they open are specific and recognizable to any operator in the space:
Biometric data privacy. Longevity clinics collect volumes of sensitive data that go far beyond a conventional medical record: genomic profiles, longitudinal biomarkers, wearable data, microbiome analyses, full-body imaging. In jurisdictions like the EU (GDPR) or states like Illinois (BIPA) and California (CCPA), handling this data requires granular consent, defined retention policies, and portability protocols that many clinics still haven’t implemented.
Regulatory gray zones and off-label use. A large portion of the longevity offering — off-label metformin, rapamycin, peptides, IV NAD+ — operates in a space where the FDA has not approved the specific indication. Off-label use is legal in the U.S. when prescribed by a physician with clinical judgment, but commercial claims about these treatments can easily cross the line into misleading advertising. When a clinic advertises “cellular rejuvenation therapy with rapamycin,” the legal department has questions.
Intellectual property of protocols. As clinics develop proprietary programs — specific biomarker combinations, intervention sequences, personalization algorithms — the question of how to protect that IP arises. Are they patentable? Are they protected as trade secrets? What happens when a physician leaves and takes the protocol to another clinic?
Why This Matters for Clinics (Not Just Startups)
When a sector enters its “industry” phase, three things happen:
- Data stops being marketing and becomes liability
- biomarkers, genomics, imaging, records: this is not a spreadsheet.
- Regulation arrives late, but it arrives
- the market runs; the rules react.
- and when they react, they react forcefully.
- Reputational risk rises
- a field that overpromises becomes a field that gets audited.
The International Dimension: EU vs. US
For clinics with international operations — or patients traveling between jurisdictions — the regulatory map is even more complex. In Europe, EMA regulation of advanced therapies establishes a strict framework for stem cell treatments and gene therapies that in some U.S. states are offered with relative freedom. GDPR imposes data protection standards that significantly exceed what HIPAA requires. And advertising criteria for medical services are more restrictive in most European countries than in the U.S. market.
That regulatory asymmetry creates opportunities (medical tourism toward more permissive jurisdictions) but also risks (patients without the protections they assume they have, clinics operating in a legal limbo between two incompatible frameworks).
Four Layers: How to Read This News as a Clinic Operator
A useful way to interpret this news is to think in “layers”:
- Layer 1: science (papers)
- Layer 2: clinical (protocols)
- Layer 3: operations (supply chain, consent, follow-up)
- Layer 4: compliance (privacy, claims, licensing, cross-border)
The announcement is Layer 4 saying: “hello.” And when Layer 4 activates, clinics that don’t have their previous layers in order will face a problem that can’t be solved with good landing page copy.
Primary source: ArentFox Schiff (press release) (Source: ArentFox Schiff (press release), 2026).